Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates

Antibody-drug conjugates (ADCs), combining monoclonal antibody with high cytotoxicity chemotherapeutic drug (warhead), have been successfully applied for clinical cancer therapy. Linker technology to select and design linker connecting warhead with antibody, is critical to the success of therapeutic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of controlled release 2015-12, Vol.220 (Pt A), p.5-17
Hauptverfasser:	Yao, Yuqin, Yu, Lin, Su, Xiaolan, Wang, Yuxi, Li, Wenting, Wu, Yangpin, Cheng, Xiangzheng, Zhang, Hang, Wei, Xian, Chen, Hao, Zhang, Rundong, Gou, Lantu, Chen, Xiaoxin, Xie, Yongmei, Zhang, Bo, Zhang, Yonghui, Yang, Jinliang, Wei, Yuquan
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibody-drug conjugates (ADCs) Bi-function linker Camptothecin - administration & dosage Camptothecin - analogs & derivatives Camptothecin - metabolism Cell Line, Tumor Female Humans Immunoconjugates - therapeutic use Mice Mice, Inbred BALB C Ovarian cancer Ovarian Neoplasms - chemistry Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Receptor, ErbB-2 - analysis SN-38 Targeting chemotherapy Trastuzumab Trastuzumab - administration & dosage Trastuzumab - metabolism Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!